L to R: Mr. Sriram Natarajan, Executive Director & Chief Executive Officer, Molbio Diagnostics Limited and Dr. Chandrasekhar Nair, Executive Director & Chief Technology Officer, Molbio Diagnostics Limited at the press conference to announce the IPO.

L to R: Molbio Diagnostics Limited team — Mr. Indraneil Borkakoty, President – Corporate Strategy, M&A, Investor Relations; Mr. Shiva Sriram, President – Business Development; Mr. Sriram Natarajan, Executive Director & Chief Executive Officer; Dr. Chandrasekhar Nair, Executive Director & Chief Technology Officer; Mr. Manan Khokhani, Chief Financial Officer & President – Finance & Accounts, at the press conference to announce the IPO of Molbio Diagnostics Limited

L to R: Mr. Kaushal Shah, Managing Director and Head – Equity Capital Markets, Kotak Mahindra Capital Company Limited; Molbio Diagnostics Limited team — Mr. Indraneil Borkakoty, President – Corporate Strategy, M&A, Investor Relations; Mr. Shiva Sriram, President – Business Development; Mr. Sriram Natarajan, Executive Director & Chief Executive Officer; Dr. Chandrasekhar Nair, Executive Director & Chief Technology Officer; Mr. Manan Khokhani, Chief Financial Officer & President – Finance & Accounts, Molbio Diagnostics Limited; Mr. Shirish Chikalge, Senior Vice President and Head – Healthcare, IIFL Capital Services Limited; and Mr. Kushagr Mathur, Assistant Vice President – Equity Capital Markets, Motilal Oswal Investment Advisors Limited at the press conference to announce the IPO of Molbio Diagnostics Limited

MUMBAI, NATIONAL, 05 AUGUST, 2026 | GPN, SACHIN MURDESHWAR:Temasek and Motilal Oswal Group-backed Molbio Diagnostics has fixed the price band for its Rs 930.7-crore initial public offering (IPO) at Rs 768-807 per share. The public issue will open for subscription on August 10 and close on August 12, while the anchor investor book will open on August 7.

Investors can bid for a minimum of 18 equity shares and in multiples thereafter. At the upper end of the price band, the IPO is valued at Rs 930.7 crore. The issue comprises a fresh issue of shares worth Rs 200 crore and an offer for sale (OFS) of 91.66 lakh shares by existing shareholders.

The IPO will open alongside the Rs 3,067-crore Dhoot Transmission public issue, making it one of two mainboard IPOs scheduled to launch on August 10. The OFS includes shares being sold by promoters Exxora Trading and Dr Chandrasekhar Bhaskaran Nair, investor India Business Excellence Fund, and seven other shareholders.

Following the issue, the promoters’ stake will dilute from the current 46.65%, while the remaining 53.35% is held by investors, including Temasek Holdings-backed V Sciences Investments and Motilal Oswal Group’s India Business Excellence Fund.

Goa-based Molbio Diagnostics develops point-of-care (POC) diagnostic solutions. Its flagship Truenat platform, patented in more than 100 countries, enables rapid molecular testing for diseases such as tuberculosis (TB), COVID-19, Hepatitis B and C, Human Immunodeficiency Virus (HIV), and Human Papillomavirus (HPV).

The PCR-based platform is designed to deliver decentralised diagnostic results within an hour, particularly in resource-constrained settings.

The company plans to utilise Rs 105.5 crore from the fresh issue proceeds to establish a research and development facility and a Centre of Excellence through its wholly owned subsidiary, Bigtec, along with office infrastructure as told to our newsman Sachin Murdeshwar. Another Rs 72.2 crore will be used to purchase plant, machinery and equipment for its manufacturing facilities in Goa and Visakhapatnam, while the remaining proceeds will be used for general corporate purposes.

The Molbio Diagnostics Management present at the IPO were Sriram Natarajan, Executive Director and Chief Executive Office; Dr. Chandrasekhar Bhaskaran Nair, Executive Director and Chief Technology Officer; Manan Bimal Khokhani, President Finance and Accounts and Chief Financial Officer; Shiva Sriram, President, Business Development and Indraneil Borkakoty, President – Corporate Strategy, Mergers and Acquisitions and Investor Relations

Molbio Diagnostics reported strong financial performance in FY26, with net profit rising 14.8% to ₹166.6 crore, while revenue increased 41.7% to ₹1,445.7 crore.Kotak Mahindra Capital Company, IIFL Capital Services and Jefferies India are the book-running lead managers to the issue.

The basis of allotment is expected to be finalised on August 13, with the company’s shares likely to list on the stock exchanges on August 17.

About Molbio Diagnostics

We are an innovative point-of-care (“POC”) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. We have developed our ‘Truenat’ platform, which is a novel POC polymerase chain reaction (“PCR”) platform that can operate in resource limited settings since its battery operated, facilitating decentralized diagnosis within an hour.

As of March 31, 2026, Truenat is patented in more than 100 countries for the diagnosis of multiple infectious and non-communicable diseases. As of March 31, 2026, we offer molecular testing for 30 diseases, including
tuberculosis (“TB”), COVID, Hepatitis B and C, Human immunodeficiency virus (“HIV”), and Human Papillomavirus (“HPV”) with 43 assays. We operate in an oligopolistic market with high entry barriers, evidenced by the fact that our platform underwent 13 years of R&D to obtain Indian Council of Medical Research (“ICMR”) certification and our ‘Truenat’ test chip for diagnosing TB is the only one by an Indian company and one of the only two rapid molecular tests in the world, which has been endorsed by the World Health Organization (“WHO”) for initial diagnosis of TB and rifampicin resistance detection using molecular diagnostic technology. (Source: 1Lattice Report). We also provide devices, enabling radiology, digital pathology and breast health screening, through our Subsidiaries, Prognosys and OptraScan and collaboration partner – UE Lifesciences. Further, we are focussed towards building a pipeline of additional products and platforms that are currently at various stages of development.

_______________ENDS________________

COMPANY STATEMENT/ PRESS RELEASE:

Price Band fixed at Rs 768 per equity share of face value Rs1 each to Rs 807 per equity share of the face value of Rs 1 each (“Equity Shares”) of Molbio Diagnostics Limited (the “Company”)
Anchor Investor Bidding Date – Friday, August 7, 2026
Bid /Offer Opening Date – Monday, August 10, 2026, and Bid/ Offer Closing Date – Wednesday, August 12, 2026
Bids can be made for a minimum of 18 Equity Shares of face value Rs1 and in multiples of 18 Equity Shares of face value Rs 1 thereafter
Employee Reservation Portion aggregating up to Rs 15 million, discount of Rs76 per Equity Share being offered to Eligible Employees
Red Herring Prospectus dated August 3, 2026 (“RHP”) link – https://www.molbiodiagnostics.com/wp-content/uploads/2026/08/Molbio-Diagnostics-Limited-Red-Herring-Prospectus.pdf

MUMBAI: Molbio Diagnostics Limited (the “Company”) proposes to open an initial public offering of its equity shares of face value of ₹1 each (“Equity Shares” and such offering the “Offer”) on Monday, August 10, 2026. The Anchor Investor Bidding Date is one Working Day prior to Bid/Offer Opening Date, being Friday, August 7, 2026. The Bid/ Offer Closing Date is Wednesday, August 12, 2026.
UPI mandate end time and date shall be at 5:00 pm on the Bid/Offer Closing Date.

The Price Band of the Offer has been fixed from Rs 768 per Equity Share of face value Rs1 each to Rs 807 per Equity Share of face value Rs1 each. Bids can be made for a minimum of 18 Equity Shares of face value Rs 1 each and multiples of 18 Equity Shares of face value Rs1 each thereafter.

The Offer comprises of a Fresh Issue of Equity Shares aggregating up to Rs2,000.00 million and an Offer for Sale of up to 91,66,000 Equity Shares by the Selling Shareholders.

The Offer for Sale includes up to 1,811,000 Equity Shares aggregating up to Rs [●] million by Exxora Trading LLP (Promoter Selling Shareholder); up to 1,221,000 Equity Shares aggregating up to Rs [●] million by Dr. Chandrasekhar Bhaskaran Nair (Promoter Selling Shareholder); up to 1,000,000 Equity Shares aggregating up to Rs [●] million by India Business Excellence Fund III (Investor Selling Shareholder); and following Other Selling Shareholders – up to 1,125,000 Equity Shares aggregating up to Rs [●] million by Gopalkrishna Mangalore Kini; up to 902,000 Equity Shares aggregating up to Rs [●] million by J. Guru Dutt; up to 902,000 Equity Shares aggregating up to Rs [●] million by Gopalakrishna Sampathgiri; up to 452,000 Equity Shares aggregating up to Rs [●] million by Sangeetha M Kini; up to 451,000 Equity Shares aggregating up to Rs [●] million by M.A. Usha Rani; up to 248,000 Equity Shares aggregating up to Rs [●] million by M.A. Rohit; up to 226,000 Equity Shares aggregating up to Rs [●] million by Shruthi G Kini; up to 202,000 Equity Shares aggregating up to Rs  [●] million by M.A. Sharath; up to 193,000 Equity Shares aggregating up to Rs [●] million by Chewbacca Services Limited; up to 193,000 Equity Shares aggregating up to Rs [●] million by Sujay Limited; up to 97,000 Equity Shares aggregating up to Rs [●] million by Shaheeda Abdul Kader; up to 78,000 Equity Shares aggregating up to Rs [●] million by Vivek Devaraj; up to 48,000 Equity Shares aggregating up to Rs [●] million by Abdul Qadir Mohamed Theruvath and up to 17,000 Equity Shares aggregating up to Rs [●] million by M Ganesh Kamath (collectively “Selling Shareholders”).

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contract (Regulation) Rules, 1957 (“SCRR”) read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”, and such portion, the “QIB Portion”), provided that our Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis (“Anchor Investor Portion”), out of which 40% shall be available for allocation as follows: (i) 33.33% for domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds and Life Insurance Companies and Pension Funds, at or above the price at which allocation will be made to Anchor Investors (“Anchor Investor Allocation Price”) in accordance with the SEBI ICDR Regulations. Any under-subscription in the portion amounting to 6.67% reserved for Life Insurance Companies and Pension Funds may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) (the “Net QIB Portion”).

Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, subject to valid Bids being received at or above the Offer Price, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. As informed to our newsman Sachin Murdeshwar however, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to all QIBs.

Further, not less than 15% of the Net Offer shall be available for allocation to Non-Institutional Bidders (out of which one-third of the portion available to Non-Institutional Bidders shall be reserved for Bidders with an application size of more than Rs 0.20 million and up to Rs 1.00 million and two-thirds shall be reserved for Bidders with an application size of more than Rs 1.00 million, provided that the unsubscribed portion in either of the aforementioned sub-categories may be allocated to Bidders in the other sub-category) and not less than 35% of the Net Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price.

Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price.

All Bidders, other than Anchor Investors, are required to participate in the Offer by mandatorily utilising the Application Supported by Blocked Amount (“ASBA”) process by providing details of their respective ASBA Account (as defined hereinafter) and UPI ID in case of UPI Bidders (as defined hereinafter), as applicable, pursuant to which their corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks (“SCSBs”) or by the Sponsor Banks under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process.

The Equity Shares of the Company are proposed to be listed on BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”) (BSE and NSE together, the “Stock Exchanges”).

Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited and Motilal Oswal Investment Advisors Limited are the Book Running Lead Managers (“BRLMs”) to the Offer.

All capitalized terms used but not defined herein shall have the meaning assigned to them in the Red Herring Prospectus.